Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency
A Phase 1, Open-Label, Randomised, Repeat Dose, Parallel Group Study to Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects Aged 10-17 Years of Age With Iron Deficiency
Sponsor: Medpace, Inc.
Listed as NCT03181451, this PHASE1 trial focuses on Iron Deficiency, Anaemia in Children and Iron-Deficiency and remains completed. Sponsored by Medpace, Inc., it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jul 2020 — Nov 2020 [monthly]
Completed PHASE1
-
Jun 2018 — Jul 2020 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Nov 2017 — Jan 2018 [monthly]
Recruiting PHASE1
-
Jun 2017 — Nov 2017 [monthly]
Recruiting PHASE1
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medpace, Inc.
- Shield Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .